Patents Assigned to The U.S.A, as represented by the Secretary, Department of Health and Human Services
  • POLYMER ADJUVANT
    Publication number: 20210000934
    Abstract: The invention relates to an adjuvant comprising Pattern Recognition Receptor (PRR) agonist molecules linked to polymer chains that are capable of undergoing particle formation in aqueous conditions, or in aqueous conditions in response to external stimuli; and methods of treatment or prevention of disease using such an adjuvant.
    Type: Application
    Filed: June 22, 2020
    Publication date: January 7, 2021
    Applicants: Oxford University Innovation Limited, The U.S.A., as Represented by the Secretary, Department of Health and Human Services
    Inventors: Kerry Fisher, Richard Laga, Geoffrey Lynn, Leonard Seymour, Robert Seder
  • Compositions and methods for treating cancer with anti-CD123 immunotherapy
    Patent number: 10844128
    Abstract: Chimeric antigen receptors containing CD123 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: November 24, 2020
    Assignees: Lentigen Technology, Inc., The U.S.A., as represented by The Secretary, Department of Health and Human Services
    Inventors: Rimas J. Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • METHODS FOR DETECTION OF FLAVIVIRUS ANTIBODIES
    Publication number: 20200348299
    Abstract: Isolated peptides that include one or more antigenic sites of Zika virus (ZIKV) and methods of their use and production are disclosed. The peptides can be used, for example, to detect exposure of a subject to a flavivirus infection, such as a ZIKV infection.
    Type: Application
    Filed: March 26, 2020
    Publication date: November 5, 2020
    Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventor: Surender Khurana
  • RECOMBINANT RESPIRATORY SYNCYTIAL VIRUS STRAINS WITH MUTATIONS IN THE M2-2 ORF PROVIDING A RANGE OF ATTENUATION PHENOTYPES
    Publication number: 20200283740
    Abstract: Provided herein are novel recombinant respiratory syncytial viruses (RSV) having an attenuated phenotype that contain mutations in the M2-2 open reading frame that interfere with the expression of the M2-2 protein. The M2-2 mutations may be present in combination with mutations at other loci. Using methods described herein, combinations of mutations are provided to achieve desired levels of attenuation. The recombinant RSV strains described here are suitable for use as live-attenuated RSV vaccines. Also provided are polynucleotide sequences of the described viruses, as well as methods for producing and using the viruses.
    Type: Application
    Filed: May 18, 2020
    Publication date: September 10, 2020
    Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Peter L. Collins, Ursula J. Buchholz, Cindy Luongo
  • Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
    Patent number: 10759846
    Abstract: Methods of inducing an immune response in a subject to the Middle East respiratory syndrome coronavirus (MERS-CoV) are provided. In several embodiments, the immune response is a protective immune response that inhibits or prevents MERS-CoV infection in the subject. Recombinant MERS-CoV polypeptides and nucleic acid molecules encoding same are also provided. Additionally, neutralizing antibodies that specifically bind to MERS-CoV S protein and antigen binding fragments thereof are disclosed. The antibodies and antigen binding fragments are useful, for example, in methods of detecting MERS-CoV S protein in a sample or in a subject, as well as methods of preventing and treating a MERS-CoV infection in a subject.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: September 1, 2020
    Assignee: The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Barney Graham, Wing-Pui Kong, Kayvon Modjarrad, Lingshu Wang, Wei Shi, Michael Gordon Joyce, Masaru Kanekiyo, John Mascola
  • CHIMERIC REPORTER WEST NILE/DENGUE VIRUSES AND THEIR USE
    Publication number: 20200255479
    Abstract: Chimeric flaviviruses engineered to contain a reporter gene and chimeric nucleic acid molecules encoding the chimeric flaviviruses are described. The chimeric flaviviruses further include genomic non-coding regions, non-structural proteins, and at least a portion of a capsid (C) protein from West Nile virus (WNV), and premembrane (prM) and envelope (E) proteins from dengue virus (DENV). Diagnostic assays that utilize chimeric West Nile/dengue viruses are further described.
    Type: Application
    Filed: August 17, 2018
    Publication date: August 13, 2020
    Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventor: Claire Y. Kinney
  • METHODS FOR THE DETECTION OF TAU PROTEIN AGGREGATES
    Publication number: 20200249245
    Abstract: Methods are disclosed herein for determining whether a subject has a Tauopathy, such as Pick disease, Alzheimer disease, progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) or argyrophilic grain disease (AGD). These methods utilize an amyloid seeding assay.
    Type: Application
    Filed: December 29, 2017
    Publication date: August 6, 2020
    Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Byron Winslow Caughey, Eri Saijo, Allison Lindsey Kraus, Michael Anthony Metrick, II
  • USES OF MESOTHELIN-TARGETED CHIMERIC ANTIGEN RECEPTORS
    Publication number: 20200239569
    Abstract: The presently disclosed subject matter provides for methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to chimeric antigen receptors (CARs) that specifically target human mesothelin, and immunoresponsive cells comprising such CARs. The presently disclosed mesothelin-targeted CARs have enhanced immune-activating properties, including anti-tumor activity.
    Type: Application
    Filed: March 17, 2020
    Publication date: July 30, 2020
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, The U.S.A. as Represented by the Secretary, Department of Health and Human Services
    Inventors: Prasad S. Adusumilli, Michel Sadelain, Dimiter S. Dimitrov, Yang Feng
  • ASSAY FOR THE DETECTION OF ALPHA-SYNUCLEIN SEEDING ACTIVITY ASSOCIATED WITH SYNUCLEINOPATHIES
    Publication number: 20200232996
    Abstract: Methods are disclosed for determining whether a subject has a synucleinopathy. Methods are also disclosed for detecting misfolded alpha synuclein (?Syn) in a biological sample or fraction thereof. These methods include the use of an ?Syn seeding assay.
    Type: Application
    Filed: September 26, 2018
    Publication date: July 23, 2020
    Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Byron Winslow Caughey, Bradley Richard Groveman, Christina Doriana Groveman, Lynne DePuma Raymond, Andrew Gregory Hughson
  • HUMAN MONOCLONAL ANTIBODY TARGETING TNFR2 FOR CANCER IMMUNOTHERAPY
    Publication number: 20200230173
    Abstract: A human monoclonal antibody that specifically binds tumor necrosis factor receptor 2 (TNFR2), and a defucosylated form of the antibody, are described. The TNFR2-specific antibody was isolated from a human scFv phage display antibody library. The disclosed antibodies promote antibody-dependent cell-mediated cytotoxicity (ADCC) of human TNFR2+ CD4+ T regulatory cells in a dose- and time-dependent manner. Methods of using the TNFR2 antibodies, such as for tumor immunotherapy, are described.
    Type: Application
    Filed: May 8, 2018
    Publication date: July 23, 2020
    Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Joost J. Oppenheim, Dimiter S. Dimitrov, De Yang, Xin Chen, Zhongyu Zhu
  • MONOCLONAL ANTIBODIES TARGETING GLYPICAN-2 (GPC2) AND USE THEREOF
    Publication number: 20200216558
    Abstract: A panel of human variable heavy (VH) single domain monoclonal antibodies specific for cell-surface glypican-2 (GPC2) are described. Methods for the diagnosis and treatment and GPC2-positive cancer are also described. Recombinant immunotoxins comprised of a GPC2-specific VH domain antibody and a clinically used form of Pseudomonas exotoxin A (PE38) were generated and shown to inhibit GPC2-positive neuroblastoma tumor cell growth and inhibit neuroblastoma xenograft growth in nude mice, without significant toxicity. Chimeric antigen receptors comprising a GPC2-specific VH single domain antibody are also described. T cells expressing the GPC2-specific CARs potently killed GPC2-positive neuroblastoma cells in a dose-dependent manner.
    Type: Application
    Filed: July 20, 2017
    Publication date: July 9, 2020
    Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Mitchell Ho, Nan Li, Dimiter S. Dimitrov
  • METHOD AND DEVICE FOR DETECTING ANTIGEN-SPECIFIC ANTIBODIES IN A BIOLOGICAL FLUID SAMPLE BY USING NEODYMIUM MAGNETS
    Publication number: 20200166505
    Abstract: Methods for detecting antigen-specific antibodies in a biological sample are described. The disclosed methods can be used for the diagnosis of a variety of autoimmune and infectious diseases. The methods use a neodymium magnet to efficiently isolate immune complexes. The disclosed methods are rapid, highly specific and sensitive, require very small volumes of biological sample, and do not require the use of radioactivity. With these advantageous features, the disclosed methods are amendable for point-of-care testing (POCT), which is currently not available for the detection of autoantibodies associated with autoimmune disease or for the detection of many pathogen-specific antibodies.
    Type: Application
    Filed: January 30, 2020
    Publication date: May 28, 2020
    Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventor: Peter D. Burbelo
  • Mesothelin-targeted chimeric antigen receptors and uses thereof
    Patent number: 10633441
    Abstract: The presently disclosed subject matter provides for methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to chimeric antigen receptors (CARs) that specifically target human mesothelin, and immunoresponsive cells comprising such CARs. The presently disclosed mesothelin-targeted CARs have enhanced immune-activating properties, including anti-tumor activity.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: April 28, 2020
    Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, The U.S.A. as Represented by the Secretary, Department of Health and Human Services
    Inventors: Prasad S. Adusumilli, Michel Sadelain, Dimiter S. Dimitrov, Yang Feng
  • Selective oxidation of 5-methylcytosine by TET-family proteins
    Patent number: 10612076
    Abstract: The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: April 7, 2020
    Assignees: The Children's Medical Center Corporation, The U.S.A., As Represented by the Secretary, Department of Health & Human Services
    Inventors: Anjana Rao, Mamta Tahiliani, Kian Peng Koh, Suneet Agarwal, Aravind Iyer
  • RAPID DETECTION OF ZIKA VIRUS BY REVERSE TRANSCRIPTION LOOP-MEDIATED ISOTHERMAL AMPLIFICATION
    Publication number: 20200063216
    Abstract: A highly sensitive and specific reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay to detect ZIKV nucleic acid in biological samples is described. The disclosed assay is capable of detecting as few as one RNA copy per ?l and can be performed in a clinical or field setting with minimal equipment and technological expertise. Oligonucleotide primers and kits for detecting ZIKV nucleic acid are also described.
    Type: Application
    Filed: April 27, 2018
    Publication date: February 27, 2020
    Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventor: Amanda E. Calvert
  • HUMAN ROTAVIRUS STRAINS AND VACCINES
    Publication number: 20200054735
    Abstract: A vaccine composition and method of vaccination are provided useful for immunizing a subject against a rotavirus. The vaccines include rotavirus strains CDC-9 and CDC-66, fragments thereof, homologues thereof, or combinations thereof. Inventive vaccines may include a fragment of CDC-9, CDC-66, homologues thereof, or combinations thereof. Methods of inducing an immunological response are provided by administering an inventive vaccine.
    Type: Application
    Filed: November 1, 2019
    Publication date: February 20, 2020
    Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Baoming Jiang, Roger I. Glass, Yuhuan Wang, Jon Gentsch
  • Compositions and methods for treating cancer with anti-mesothelin immunotherapy
    Patent number: 10550179
    Abstract: Chimeric antigen receptors containing mesothelin antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: February 4, 2020
    Assignees: Lentigen Technology Inc., The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Rimas J. Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • GENE SIGNATURE PREDICTIVE OF HEPATOCELLULAR CARCINOMA RESPONSE TO TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE)
    Publication number: 20200032345
    Abstract: This disclosure provides methods for predicting the likelihood that a hepatocellular carcinoma (HCC) will respond to transcatheter arterial chemoembolization (TACE) using a gene signature of 14 or 15 genes. Also provided are nucleic acid probes and kits for detecting the gene signature.
    Type: Application
    Filed: February 7, 2017
    Publication date: January 30, 2020
    Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Xin Wei Wang, Valerie Fako Miller
  • Compositions and methods for treating cancer with anti-CD22 immunotherapy
    Patent number: 10543263
    Abstract: Chimeric antigen receptors (CARs) containing CD22 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the CARs are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making CAR T cells are also disclosed.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: January 28, 2020
    Assignees: Lentigen Technology Inc., The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Rimas J. Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • Mesothelin-targeted chimeric antigen receptors and methods of making them
    Patent number: 10538588
    Abstract: The presently disclosed subject matter provides for methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to chimeric antigen receptors (CARs) that specifically target human mesothelin, and immunoresponsive cells comprising such CARs. The presently disclosed mesothelin-targeted CARs have enhanced immune-activating properties, including anti-tumor activity.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: January 21, 2020
    Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, THE U.S.A. AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Prasad S. Adusumilli, Michel Sadelain, Dimiter S. Dimitrov, Yang Feng